These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 29862466)

  • 21. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients.
    Akers KS; Niece KL; Chung KK; Cannon JW; Cota JM; Murray CK
    J Trauma Acute Care Surg; 2014 Sep; 77(3 Suppl 2):S163-70. PubMed ID: 24770557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
    Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
    J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy.
    Butragueño-Laiseca L; Marco-Ariño N; Troconiz IF; Grau S; Campillo N; García X; Padilla B; Fernández SN; Slöcker M; Santiago MJ
    Clin Microbiol Infect; 2022 Sep; 28(9):1287.e9-1287.e15. PubMed ID: 35390523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
    Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
    Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
    J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
    Patel N; Scheetz MH; Drusano GL; Lodise TP
    Antimicrob Agents Chemother; 2010 Jan; 54(1):460-5. PubMed ID: 19858253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.
    Kalaria SN; Gopalakrishnan M; Heil EL
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Thy M; Urien S; Bouazza N; Foissac F; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
    Clin Pharmacokinet; 2022 Nov; 61(11):1609-1621. PubMed ID: 36251162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.
    Zander J; Döbbeler G; Nagel D; Maier B; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
    Crit Care; 2016 Apr; 20():79. PubMed ID: 27039986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.
    Sukarnjanaset W; Jaruratanasirikul S; Wattanavijitkul T
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):251-261. PubMed ID: 30963365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
    Tamme K; Oselin K; Kipper K; Tasa T; Metsvaht T; Karjagin J; Herodes K; Kern H; Starkopf J
    Acta Anaesthesiol Scand; 2016 Feb; 60(2):230-40. PubMed ID: 26830215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.